Changchun GeneScience Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1948-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://english.ciac.cas.cn/
A Study to Investigate the Safety and Efficacy of Once-weekly PEG-somatropin (GenSci004) in Children With Growth Hormone Deficiency
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT06024967
A Study to Investigate Efficacy and Safety of Weekly PEG-somatropin (GenSci004) in Treatment Naive Children With Growth Hormone Deficiency
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 162
- Registration Number
- NCT06007417
- Locations
- 🇺🇸
Cook Childrens, Fort Worth, Texas, United States
Safety & Efffficacy of Genakumab in Patients With Frequent Flares
Phase 3
Completed
- Conditions
- Acute Gout Arthritis
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 313
- Registration Number
- NCT05983445
- Locations
- 🇨🇳
Fudan University Affiliated Huashan Hospital, Shanghai, Shanghai, China
A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202)
Phase 2
Completed
- Conditions
- GoutGout Initiating Urate-loweringUrate-lowering Therapy
- Interventions
- Drug: Genakumab for injection
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 165
- Registration Number
- NCT05936281
- Locations
- 🇨🇳
Fudan University Affiliated Huashan Hospital, Shanghai, Shanghai, China
Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare
Phase 2
Completed
- Conditions
- Acute GoutGout Flare
- Interventions
- Drug: Genakumab for injection
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 106
- Registration Number
- NCT05936268
- Locations
- 🇨🇳
Fudan University Affiliated Huashan Hospital, Shanghai, Shanghai, China
To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.
Phase 2
Not yet recruiting
- Conditions
- Active Systemic Juvenile Idiopathic Arthritis
- Interventions
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05925452
- Locations
- 🇨🇳
Children's Hospital Affiliated to Capital Medical University, Beijing, Benjing, China
🇨🇳Children's Hospital Affiliated to Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳Hunan Children's Hospital, Changsha, Hunan, China
To Evaluate the Safety and Tolerability of Multiple Doses of GS3-007a Oral Solution in Healthy Subjects.
Phase 1
Completed
- Conditions
- Healthy Subject
- Interventions
- Drug: GS3-007 oral liquid
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT05921890
- Locations
- 🇨🇳
Chengdu Xinhua Hospital Affiliated to North Sichuan Medical College, Chengdu, Sichuan, China
Gentuximab Combined With Paclitaxel Compared With Placebo Combined With Paclitaxel for Gastric Adenocarcinoma.
Phase 3
Recruiting
- Conditions
- Adenocarcinoma of Stomach
- Interventions
- Drug: Gentuximab InjectionDrug: Gentuximab Injection Placebo
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 752
- Registration Number
- NCT05919381
- Locations
- 🇨🇳
Shanghai Dongfang Hospital, Shanghai, Shanghai, China
Clinical Study of Multiple Dose Genakumab for Injection in Chinese Healthy Adults
Phase 1
Completed
- Conditions
- Interstitial Lung Disease
- Interventions
- Drug: placebo
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05894148
- Locations
- 🇨🇳
Chengdu Xinhua Hospital Affiliated to North Sichuan Medical College, Chengdu, Sichuan, China
A Phase 2, Randomized, Placebo-controlled, Double-blind Study of EG017 in Female Patients With Stress Urinary Incontinence
Phase 2
Completed
- Conditions
- Stress Urinary Incontinence
- Interventions
- Drug: EG017 3mgDrug: EG017 6mg
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 51
- Registration Number
- NCT05674045
- Locations
- 🇨🇳
People's Hospital of Peking University, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath